ABRYSVO

(respiratory syncytial virus vaccine, (bivalent, recombinant))

Find ABRYSVO medical information:

Find ABRYSVO medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

ABRYSVO Quick Finder

▼ This medicinal product is subject to additional monitoring, which will allow the rapid identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.

The Abrysvo Summary of Product Characteristics (SmPC) is available here.

Abrysvo is indicated for:

  • Active immunisation of pregnant individuals to protect infants from birth through 6 months of age against lower respiratory tract disease caused by respiratory syncytial virus (RSV).
  • Active immunisation of individuals 18 years of age and older for the prevention of lower respiratory tract disease caused by RSV.

The use of this vaccine should be in accordance with official recommendations.

Didn’t find what you were looking for? 

Contact us

Call 01 58 07 34 40*

*Contact Medical Information. 09h - 18h Monday to Friday.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety 

To report an adverse event related to a Pfizer product, click on the link:
www.pfizersafetyreporting.com
If you cannot use the above website, please contact Pfizer pharmacovigilance at FRA.AEReporting@pfizer.com.

Governmental website 

You may also report adverse events online on the Ministry of Health’s website ‘Portail de signalement des événements sanitaires indésirables’ at https://signalement.social-sante.gouv.fr